

## LIST OF PUBLICATIONS

Biondini D, Balestro E, Lacedonia D, Cerri S, Milaneschi R, Luppi F, Coconcelli E, Bazzan E, Clini E, Foschino Barbaro MP, Gregori D, Cosio MG, Saetta M, **Spagnolo P**. Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis. *Sci Rep*. 2018 Apr 13;8(1):5961. doi: 10.1038/s41598-018-24303-4.

**Spagnolo P**, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU. Pulmonary sarcoidosis. *Lancet Respir Med*. 2018 Apr 3. pii: S2213-2600(18)30064-X. doi: 10.1016/S2213-2600(18)30064-X. [Epub ahead of print]

Rothe T, **Spagnolo P**, Bridevaux PO, Clarenbach C, Eich-Wanger C, Meyer F, Miedinger D, Möller A, Nicod LP, Nicolet-Chatelain G, Sauty A, Steurer-Stey C, Leuppi JD. Diagnosis and Management of Asthma - The Swiss Guidelines. *Respiration*. 2018 Apr 3. doi: 10.1159/000486797. [Epub ahead of print]

Harari S, Caminati A, Poletti V, Confalonieri M, Gasparini S, Lacedonia D, Luppi F, Pesci A, Sebastiani A, **Spagnolo P**, Vancheri C, Balestro E, Bonifazi M, Cerri S, De Giacomo F, Della Porta R, Foschino Barbaro MP, Fui A, Pasquinelli P, Rosso R, Tomassetti S, Specchia C, Rottoli P; for the ILDINET (Interstitial Lung Diseases Italian Network). A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis. *Respiration*. 2018 Mar 27. doi: 10.1159/000487711. [Epub ahead of print]

Mengoli MC, Rossi G, Cavazza A, Franco R, Marino FZ, Migaldi M, Gnetti L, Silini EM, Ampollini L, Tiseo M, Lococo F, Fournel L, **Spagnolo P**, Cottin V, Colby TV. Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) Syndrome and Carcinoid Tumors With/Without NECH: A Clinicopathologic, Radiologic, and Immunomolecular Comparison Study. *Am J Surg Pathol* 2018; 42(5): 646-55

Tzouvelekis A, **Spagnolo P**, Bonella F, Vancheri C, Tzilias V, Crestani B, Kreuter M, Bouros D. Patients with IPF and lung cancer: diagnosis and management. *Lancet Respir Med* 2018; 6(2): 86-8

Rossi G, Longo L, Barbieri F, Bertolini F, **Spagnolo P**. Large cell neuroendocrine carcinoma of the lung: chemotherapy regimen depends on how "large" your diagnostic criteria are. *Eur Respir J* 2017 Oct 26;50(4). pii: 1701292. doi: 10.1183/13993003.01292-2017

Rossi G, Cavazza A, **Spagnolo P**, Bellafiore S, Kuhn E, Carassai P, Caramanico L, Montanari G, Capiello G, Andreani A, Bono F, Nannini N. The role of macrophages in interstitial lung diseases. *Eur Respir Rev* 2017 Jul 19;26(145). pii: 170009. doi: 10.1183/16000617.0009-2017.

Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, Inoue Y, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johannson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, **Spagnolo P**, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts W, Hansell D, Wells A; IPF Project Consortium. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. *Eur Respir J*. 2017 Aug 31;50(2). pii: 1700936. doi: 10.1183/13993003.00936-2017

Rossi G, **Spagnolo P**. Biopsy in idiopathic pulmonary fibrosis: back to the future. *Exp Rev Respir Med* 2017; 11(9): 679-84

**Spagnolo P**, Wuyts W. Acute exacerbations of interstitial lung disease: lessons from idiopathic pulmonary fibrosis. *Curr Opin Pulm Med* 2017; 23(5): 411-7

**Spagnolo P**, Maher TM. Clinical trial research in focus: why do so many clinical trials fail in IPF? *Lancet Respir Med* 2017; 5(5): 372-4

Kreuter M, **Spagnolo P**, Wuyts W, Renzoni E, Koschel D, Bonella F, Maher TM, Kolb M, Weycker D, Kirchgässler K-U, Costabel U. Antacid Therapy and Disease Progression in Patients With IPF Who Received Pirfenidone. *Respiration* 2017; 93(6): 415-23

**Spagnolo P**, Oldham JM, Jones MG, Lee JS. Personalized medicine in interstitial lung diseases. *Curr Opin Pulm Med* 2017; 23(3): 231-6

Meier T, Rummey C, Leinonen M, **Spagnolo P**, Mayer OH and Buyse GM for the DELOS Study Group. Characterization of pulmonary function in 10-18 year old patients with Duchenne muscular dystrophy. *Neuromuscular Disorders* 2017; 27(4): 307-14

**Spagnolo P**, Cottin V. Genetics of idiopathic pulmonary fibrosis: from mechanistic pathways to personalized medicine. *J Med Genet* 2017; 54(2): 93-9

Ahmad K, Barba T, Gamondes D, Ginoux M, Khouatra C, **Spagnolo S**, Strek S, Thivolet-Béjui F, Traclet J, Cottin V. Interstitial pneumonia with autoimmune features: clinical, radiologic, and histological characteristics and outcome in a series of 57 patients. *Respir Med* 2017; 123: 56-62

**Spagnolo P**. Pirfenidone and mortality in idiopathic pulmonary fibrosis. *Lancet Respir Med* 2017; 5(1): 3-5

**Spagnolo P**, Sverzellati N, Rossi G. Idiopathic Pulmonary Fibrosis in 2016: towards a better diagnosis. *Lancet Respir Med* 2016; 4(12): 945-7

Wuyts WA, **Spagnolo P**, Bonella F, Yserbyt J, Verleden GM. Daily Home Spirometry: A New Milestone in the Field of Pulmonary Fibrosis. *Am J Respir Crit Care Med* 2016;194(8):1033-4

Buyse GM, Voit T, Schara U, Straathof CS, D'Angelo MG, Bernert G, Cuisset JM, Finkel RS, Goemans N, Rummey C, Leinonen M, Mayer OH, **Spagnolo P**, Meier T, McDonald CM; DELOS Study Group. Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy. *Pediatr Pulmonol* 2017; 52(4): 508-15

Kreuter M, Bonella F, Maher TM, Costabel U, **Spagnolo P**, Weycker D, Kirchgaessler KU, Kolb M. Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. *Thorax* 2017; 72(2): 148-53

**Spagnolo P**, Bush A. Interstitial lung disease in children younger than 2 years. *Pediatrics* 2016 Jun;137(6). pii: e20152725. doi: 10.1542/peds.2015-2725.

**Spagnolo P**, Sverzellati N, Rossi G. Is the imaging *inconsistent with* usual interstitial pneumonia? Think about idiopathic pulmonary fibrosis then! *Respirology* 2016; 21(5): 782-4

McDonald CM, Meier T, Voit T, Schara U, Straathof CS, D'Angelo MG, Bernert G, Cuisset JM, Finkel RS, Goemans N, Rummey C, Leinonen M, **Spagnolo P**, Buyse GM; DELOS Study Group. Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy. *Neuromuscul Disord* 2016; 26(8): 473-80

Balestro E, Calabrese F, Turato G, Lunardi F, Bazzan E, Marulli G, Biondini D, Rossi E, Sanduzzi A, Rea F, Rigobello C, Gregori D, Baraldo S, **Spagnolo P**, Cosio MG, Saetta M. Immune inflammation and disease progression in idiopathic pulmonary fibrosis. *PLoS One* 2016; 11(5): e0154516

Kreuter M, Wuyts W, Renzoni E, Koschel D, Maher TM, Kolb M, Weycker D, **Spagnolo P**, Kirchgaessler KU, Herth FJ, Costabel U. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. *Lancet Respir Med* 2016; 4(5): 381-9

Kreuter M, Wijsenbeek MS, Vasakova M, **Spagnolo P**, Kolb M, Costabel U, Weycker D, Kirchgaessler KU, Maher TM. Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. *Eur Respir J* 2016; 47(6): 1776-84

Rossi G, Cavazza A, **Spagnolo P**, Sverzellati N, Longo L, Jukna A, Montanari G, Carbonelli C, Vincenzi G, Bogina G, Franco R, Tiseo M, Cottin V, Colby TV. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia syndrome. *Eur Respir J* 2016; 47(6): 1829-41

Borie R, Justet A, Beltramo G, Manali ED, Pradère P, **Spagnolo P**, Crestani B. Pharmacological management of IPF. *Respirology* 2016; 21(4): 615-25

Wuyts WA, Bonella F, Costabel U, Cottin V, Kreuter M, Poletti V, **Spagnolo P**. An important step forward, but still a way to go. *Am J Respir Crit Care Med* 2016; 193(3): 340-1

Sisson TH, **Spagnolo P**. Matriptase, Protease-activated Receptor 2, and Idiopathic Pulmonary Fibrosis. Further Evidence for Signaling Pathway Redundancy in this Difficult-to-Treat Disease? *Am J Respir Crit Care Med* 2016; 193(8): 816-7

**Spagnolo P**, Cordier J-F, Cottin V. Connective tissue diseases, multimorbidity and the ageing lung. *Eur Respir J* 2016; 47(5): 1535-58

Lococo F, Mengoli MC, **Spagnolo P**, Cavazza A, Rossi G. Chickenpox-Related Multiple Pulmonary Granulomas: A Poorly Recognized Entity. *Lung* 2016; 194(2): 329-30

Lococo F, Montanari G, Mengoli MC, Ferrari F, **Spagnolo P**, Rossi G. Haemoptysis and Progressive Dyspnoea in a 67-year-old Woman with History of Renal Transplantation. *Am J Respir Crit Care Med* 2016; 193(6): e12-3

Kreuter M, Bonella M, Wijzenbeek M, Maher TM, **Spagnolo P**. Pharmacological treatment of idiopathic pulmonary fibrosis: current approaches, unsolved issues and future perspectives. *Biomed Res Int* 2015; 2015: 329481

**Spagnolo P**, Bonella F, Maher TM. New guideline on treatment of idiopathic pulmonary fibrosis. *Lancet Respir Med* 2015; 3(9): e31-2

Truini A, Santos Pereira P, Cavazza A, **Spagnolo P**, Nosseir S, Longo L, Jukna A, Lococo F, Vincenzi G, Bogina G, Tiseo M, Rossi G. Classification of different patterns of pulmonary adenocarcinomas. *Expert Rev Respir Med* 2015; 9(5): 571-86

**Spagnolo P**, Rossi G, Cavazza A, Bonifazi M, Paladini I, Bonella F, Sverzellati N, Costabel U. Hypersensitivity pneumonitis: a comprehensive review. *J Investig Allergol Clin Immunol* 2015; 25(4): 237-50

**Spagnolo P**, Tzouveleakis A, Maher TM. Personalized medicine in idiopathic pulmonary fibrosis: facts and promises. *Curr Opin Pulm Med* 2015; 21(5): 470-8

**Spagnolo P**, Maher TM, Richeldi L. Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy. *Pharmacol Ther* 2015; 152: 18-27

Grunewald J, **Spagnolo P**, Wahlström, Eklund A. Immunogenetics of disease-causing inflammation in sarcoidosis. *Clin Rev Allergy Immunol* 2015; 49(1): 19-35

**Spagnolo P**. Sarcoidosis: A critical review of history and milestones. *Clin Rev Allergy Immunol* 2015; 49(1): 1-5

Tzouveleakis A, Bonella F, **Spagnolo P**. Update on therapeutic management of idiopathic pulmonary fibrosis. *Ther Clin Risk Manag* 2015; 11: 359-70

**Spagnolo P**, Sverzellati N, Rossi G, Cavazza A, Tzouveleakis A, Crestani B, Vancheri C. Idiopathic pulmonary fibrosis: an update. *Ann Med* 2015; 47(1): 15-27

**Spagnolo P**. Novel treatments for idiopathic pulmonary fibrosis. *Am J Med* 2015; 128(5): 447-9

**Spagnolo P**, Wells AU, Collard HR. Pharmacological treatments of idiopathic pulmonary fibrosis: an update. *Drug Discov Today* 2015; 20(5): 514-24

Codeluppi L, **Spagnolo P**, Tondelli M, Malaguti MC, Mandrioli J. Recurrent cerebrospinal fluid basophilia in neurosarcoidosis. *Acta Neurol Belg* 2015; 115(3): 497-9

Wuyts WA, Cavazza A, Rossi G, Bonella F, Sverzellati N, **Spagnolo P**. Differential diagnosis of usual interstitial pneumonia - when is it truly *idiopathic*? *Eur Respir Rev* 2014; 23: 308-19

Greco FG, **Spagnolo P**, Muri M, Paladini I, Chizzolini F, Piciocchi S, Colombi D, Sverzellati N. The value of chest radiograph and computed tomography in pulmonary sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Dis* 2014; 31(2): 108-16

Fischer A, Grunewald J, **Spagnolo P**, Nebel A, Schreiber S, Müller-Quernheim J. Genetics of sarcoidosis. *Semin Respir Crit Care Med* 2014; 35(3): 296-306

**Spagnolo P**, Rossi G, Cavazza A. Pathogenesis of idiopathic pulmonary fibrosis and its clinical implications. *Expert Rev Clin Immunol* 2014; 10(8):1005-17

**Spagnolo P**, Grunewald J, du Bois RM. Genetic determinants of pulmonary fibrosis - evolving concepts. *Lancet Respir Med* 2014; 2(5): 416-28

**Spagnolo P**, Sverzellati N, Wells AU, Hansell DM. Imaging aspects of the diagnosis of sarcoidosis. *Eur Radiol* 2014; 24(4): 807-16

Zappala C, Desai S, Copley S, **Spagnolo P**, Cramer D, Sen D, Alam S, du Bois RM, Hansell DM, Wells AU. Accuracy of individual variables in the monitoring of long-term change in pulmonary sarcoidosis as judged by serial HRCT data. *Chest* 2014 145(1): 101-7

**Spagnolo P**, du Bois RM, Cottin V. Rare (orphan) lung disease and drug development: current status and future challenges. *Lancet Respir Med*. 2013; 1(6): 479-87

**Spagnolo P**, Grunewald J. Recent Advances in the Genetics of Sarcoidosis. *J Med Genet* 2013; 50(5): 290-7

Sverzellati N, Randi G, **Spagnolo P**, Marchianò A, Silva M, Kuhnigk JM, La Vecchia C, Zompatori M, Pastorino U. Increased mean lung density: another independent predictor of lung cancer? *Eur J Radiol* 2013; 82(8): 1325-31

**Spagnolo P**, Maher TM, Luppi F, Wuyts WA, Grutters JC. Primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis: one step at a time. *Am J Respir Crit Care Med* 2013; 187(11): 1271-2

**Spagnolo P**, Schwartz DA. Genetic predisposition to sarcoidosis - another brick in the wall. *Eur Respir J* 2013; 41(4): 778-80

**Spagnolo P**, Fabbri LM, Bush A. Long-term macrolide treatment for chronic respiratory disease. *Eur Respir J* 2013; 42(1): 239-51

**Spagnolo P**, Luppi F, Richeldi L. The reply. *Am J Med* 2013;126(1): e19

**Spagnolo P**, Tonelli R, Cocconcelli E, Stefani A, Richeldi L. Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges. *Multidiscip Respir Med* 2012; 7(1): 42

**Spagnolo P**, Luppi F, Cerri S, Richeldi L. Genetic testing in diffuse parenchymal lung disease. *Orphanet J Rare Dis* 2012; 7(1): 79

Colaci M, Giuggioli D, Manfredi A, Sebastiani M, **Spagnolo P**, Luppi F, Cerri S, Richeldi L, Ferri C. Lung cancer in scleroderma: results from a single rheumatologic centre and review of the literature. *Autoimmun Rev* 2013; 12(3): 374-9

Luppi F, **Spagnolo P**, Cerri S, Richeldi L. The big clinical trials in IPF. *Curr Opin Pulm Med* 2012; 18(5): 428-32

Cerri S, **Spagnolo P**, Luppi F, Richeldi L. Management of Idiopathic Pulmonary Fibrosis. *Clin Chest Med* 2012; 33(1): 85-94

Contini P, Schiavina M, Schiavina R, Tavalazzi F, Fabiani A, Di Scioscio V, **Spagnolo P**, Richeldi L. Efficacy of hormonal suppression in a patient with chyluria due to lymphangiomyomatosis. *Multidiscip Respir Med* 2011; 6(5): 313-7

Zappala CJ, Desai SR, Copley SJ, **Spagnolo P**, Cramer D, Sen D, Alam SM, du Bois RM, Hansell DM, Wells AU. Optimal scoring of serial change on chest radiography in sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Dis* 2011; 28(2): 130-8

Baughman RP, Nagai S, Balter M, Costabel U, Drent M, du Bois R, Grutters JC, Judson MA, Lambiri I, Lower EE, Muller-Quernheim J, Prasse A, Rizzato G, Rottoli P, **Spagnolo P**, Teirstein A. Defining the clinical outcome status (COS) in sarcoidosis: Results of WASOG task force. *Sarcoidosis Vasc Diffuse Lung Dis* 2011; 28(1): 56-64

Luppi F, Covi M, Velluti G, **Spagnolo P**, Fabbri LM, Richeldi L. Co-trimoxazole effect on human alveolar macrophages of AIDS patients. *J Biol Regul Homeost Agents* 2011; 25(3): 461-4

**Spagnolo P**, Luppi F, Roversi P, Cerri S, Fabbri LM, Richeldi L. Sarcoidosis: challenging diagnostic aspects of an old disease. *Am J Med* 2011; 125(2): 118-25

Cerri S, du Bois RM, **Spagnolo P**. Genetic commonality between inflammatory bowel disease and sarcoidosis. *Eur Respir J* 2011; 37(3): 489-91

Sato H, Woodhead F, Ahmad T, Grutters JC, **Spagnolo P**, van den Bosch J, Maier L, Newman LS, Nagai S, Izumi T, Wells AU, du Bois RM, Welsh KI. Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups. *Hum Mol Gen* 2010; 19: 4100-11

**Spagnolo P**, Del Giovane C, Luppi F, Cerri S, Balduzzi S, Walters EH, D'Amico R, Richeldi L. Non-steroid agents for idiopathic pulmonary fibrosis. *Cochrane Database Syst Rev* 2010; 9: CD003134

Sato H, Silveira L, **Spagnolo P**, Gillespie M, Gottschall EB, Welsh KI, du Bois RM, Newman LS, Maier LA. C-C chemokine receptor 5 (CCR 5) polymorphisms in beryllium disease. *Eur Respir J* 2010; 36: 331-8

- Spagnolo P**, Zeuzem S, Richeldi L, du Bois RM. The complex interrelationships between chronic lung and liver disease: a review. *J Viral Hepat* 2010; 17: 381-90
- Canali E, Sola P, Richeldi L, **Spagnolo P**, Mora G, Georgouloupoulou E, Bernabei C, Bigliardi G, Valzania F, Mandrioli J. Amyotrophic Lateral Sclerosis and Sarcoidosis: a difficult differential diagnosis. *Amyotroph Lateral Scler* 2010; 11: 410-1
- Colaci M, Sebastiani M, Giuggioli D, Manfredi A, **Spagnolo P**, Luppi F, Richeldi L, Ferri C. Broncho-alveolar lavage and response to cyclophosphamide in scleroderma alveolitis. *Scandinavian J Rheumatology* 2010; 39: 155-9
- Sato H, Williams HR, **Spagnolo P**, Abdallah A, Ahmad T, Orchard TR, Copley SJ, Desai SR, Wells AU, du Bois RM, Welsh KI. CARD15/NOD2 polymorphisms are associated with severe pulmonary sarcoidosis. *Eur Respir J* 2010; 35: 324-30
- Spagnolo P**, Luppi F, Rossi G, Richeldi L. To BAL or not to BAL: is this a problem in diagnosing IPF? *Am J Respir Crit Care Med* 2009; 180: 379-80
- Sverzellati N, Calabrò E, Randi G, La Vecchia C, Marchianò A, Kuhnigk JM, Zompatori M, **Spagnolo P**, Pastorino U. Sex differences in emphysema phenotypes in smokers without airflow obstruction. *Eur Respir J* 2009; 33: 1320-8
- Spagnolo P**, Richeldi L, du Bois RM. Environmental triggers and susceptibility factors in idiopathic granulomatous diseases. *Semin Respir Crit Care Med* 2008; 29: 610-9
- Spagnolo P**, Sato H, Grunewald J, Brynedal B, Hillert J, Mañá J, Wells AU, Eklund A, Welsh KI, du Bois RM. A common haplotype of the C-C chemokine receptor 2 gene and HLA-DRB1\*0301 are independent genetic risk factors for Löfgren's syndrome. *J Intern Med* 2008; 264: 433-41
- Hill TA, Lightman S, Pantelidis P, Abdallah A, **Spagnolo P**, du Bois RM. Intracellular cytokine profiles and T cell activation in pulmonary sarcoidosis. *Cytokine* 2008; 42: 289-92
- Carulli MT, **Spagnolo P**, Fonseca C, Welsh KI, du Bois RM, Black CM, Denton CP. Single-nucleotide polymorphisms in CCL2 gene are not associated with susceptibility to systemic sclerosis. *J Rheumatol* 2008; 35: 839-44
- Sverzellati N, Molinari F, Pirroni T, Bonomo L, **Spagnolo P**, Zompatori M. New insights on COPD imaging via CT and MRI. *Int J Chron Obstruct Pulmon Dis* 2007; 2: 301-12
- Sato H, **Spagnolo P**, Silveira L, Welsh KI, du Bois RM, Newman LS, Maier LA. BTNL2 allele associations with chronic beryllium disease in HLD-DPB1\*Glu69-negative individuals. *Tissue Antigens* 2007; 70: 480-6
- Fonseca C, Lindahl GE, Ponticos M, Sestini P, Renzoni EA, Holmes AM, **Spagnolo P**, Pantelidis P, Leoni P, Holmes AM, McHugh N, Stock C, Shi-Wen X, Denton CP, Black CM, Welsh KI, du Bois RM, Abraham DJ. A Functional polymorphism in the CTGF promoter is associated with risk of systemic sclerosis. *N Engl J Med* 2007; 357: 1210-20
- Spagnolo P**, Sato H, Grutters JC, Renzoni EA, Marshall SE, Ruven HJT, Wells AU, Tzouveleki A, van Moersel CHM, van den Bosch JMM, du Bois RM, Welsh KI. Analysis of BTNL2 genetic polymorphisms in British and Dutch patients with sarcoidosis. *Tissue Antigens* 2007; 70: 219-27
- Spagnolo P**, Sato H, Marshall SE, Antoniou KM, Ahmad T, Wells AU, Ahad MA, Lightman S, du Bois RM, Welsh KI. Association between Heat Shock Protein 70/Hom genetic polymorphisms and uveitis in patients with sarcoidosis. *Invest Ophthalmol Vis Sci* 2007; 48: 3019-25
- Spagnolo P**, du Bois RM. Genetics of sarcoidosis. *Clin Dermatol* 2007; 25: 242-9
- Yeo TK, Ahad MA, Kuo NW, **Spagnolo P**, Menezes V, Lympant P, Lightman S. Chemokine gene polymorphisms in idiopathic anterior uveitis. *Cytokine* 2006; 35: 29-35
- Spagnolo P**, Renzoni EA, Wells AU, Copley SJ, Desai SR, Sato H, Grutters JC, Abdallah A, Taegtmeier A, du Bois RM, Welsh KI. C-C chemokine receptor 5 gene variants in relation to lung disease in sarcoidosis. *Am J Respir Crit Care Med* 2005; 172: 721-8
- Spagnolo P**, Renzoni EA, Wells AU, Sato H, Grutters JC, Sestini P, Abdallah A, Gramiccioni E, Ruven HJ, du Bois RM, Welsh KI. C-C chemokine receptor 2 and sarcoidosis: association with Löfgren's syndrome. *Am J Respir Crit Care Med* 2003; 168: 1162-6